{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088370","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.673031+00:00","generated_at":"2026-06-12T03:55:18.417613+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cara Therapeutics updates corporate presentation; cash $102M, pipeline catalysts outlined","bullets":["Cash position $102M as of June 30, 2023, no debt, cash runway at least 12 months.","KORSUVA injection launched in US (Apr 2022) and EU (Sep 2022); Japan approval expected 2H23.","Oral difelikefalin in phase 3 for advanced CKD (KICK1/2, topline 2H24) and atopic dermatitis (KIND1/2, topline 1H25).","Phase 2/3 for notalgia paresthetica (KOURAGE1) initiated 1Q23, topline 2H26.","Partner CSL Vifor handles commercialization; Cara has no cash outlay for commercial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088370","json":"https://secwatch.observer/filing/0001104659-23-088370.json","markdown":"https://secwatch.observer/filing/0001104659-23-088370.md","text":"https://secwatch.observer/filing/0001104659-23-088370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/0001104659-23-088370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923088370/tm2322717d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:55:18.417613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}